Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 19 Apr 2024
However, because there is a chance of uncommon immune-related side effects, use should be avoided "if possible.".
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
1.
TULSA Is Effective in Long-Term Prostate Cancer Control.
2.
AVD Chemo Regimen Shows Promise in Older Patients With HL
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
5.
New Nanoparticles Can Destroy Undruggable Cancer Proteins
1.
Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations
2.
Contemporary Insights in Oncology in the Digital Era
3.
Strategic Concepts in Hematology for Modern Medicine
4.
Ferroptosis-Modulating Therapeutics in Precision Oncology
5.
Exploring the Potential of Bendamustine in Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge